Challenge of personalized health care: To what extent is medicine already individualized and what are the future trends?

Medical Science Monitor

Volumn 10, Issue 5, 2004, Pages

  Fierz, Walter ^a,b,c  

^a Institute for Clinical Microbiology and Immunology   (Switzerland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LogoLab AG   (Switzerland)

Author keywords

Infectomics; Information management; Patient centered health care; Personalized medicine; Pharmacogenomics

Indexed keywords

DRUG EFFICACY; EARLY DIAGNOSIS; ENVIRONMENT; EVIDENCE BASED MEDICINE; GENETIC VARIABILITY; HEALTH CARE; HEALTH CARE PLANNING; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFECTION; INFORMATION SYSTEM; INFORMED CONSENT; LEGAL ASPECT; MINORITY GROUP; PERSONALIZED HEALTH CARE; PHARMACOGENETICS; PHARMACOGENOMICS; PRIVACY; REVIEW; SOCIAL PSYCHOLOGY;

BIOMEDICAL TECHNOLOGY; DATABASES; DELIVERY OF HEALTH CARE; FORECASTING; HUMANS; MEDICAL INFORMATICS; MEDICINE; MODELS, BIOLOGICAL; PATIENT CARE MANAGEMENT; PATIENT-CENTERED CARE; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; TIME FACTORS;

EID: 2942726419     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Shapiro AK, Shapiro E: The Powerful Placebo: from ancient priest to modern physician. Baltimore and London: The Johns Hopkins University Press, 1997
2. White A, Slade P, Hunt C et al: Individualised homeopathy as an adjunct in the treatment of childhood asthma: a randomised placebo controlled trial. Thorax, 2003; 58(4): 317-21
3. Linde K, Vickers A, Hondras M et al: Systematic reviews of complementary therapies - an annotated bibliography. Part 1: Acupuncture. BMC Complement Altern Med, 2001; 1(1): 3. Available from: URL: http://www.biomedcentral.com/ 1472-6882/1/3
4. Linde K, ter Riet G, Hondras M et al: Systematic reviews of complementary therapies - an annotated bibliography. Part 2: Herbal medicine. BMC Complement Altern Med, 2001; 1(1): 5. Available from: URL: http://www.biomedcentral.com/ 1472-6882/1/5
5. Linde K, Hondras M, Vickers A et al: Systematic reviews of complementary therapies - an annotated bibliography. Part 3: Homeopathy. BMC Complement Altern Med, 2001; 1(1): 4. Available from: URL: http://www.biomedcentral.com/1472- 6882/1/4
6. Hrobjartsson A, Gotzsche PC: Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med, 2001; 344(21): 1594-602
7. Conti F: Claude Bernard: primer of the second biomedical revolution. Nat Rev Mol Cell Biol, 2001; 2(9): 703-08
8. McLeod HL, Evans WE: Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy. Annu Rev Pharmacol Toxicol 2001; 41(1): 101-21
9. Marshall A: Laying the foundations for personalized medicines. Nat Biotechnol, 1997; 15(10): 954-57
10. Palmer LJ, Silverman ES, Drazen JM, Weiss ST: Pharmacogenomics of Asthma Treatment. In: Licinio J, Wong M-L, editors. Pharmacogenomics: The Search for Individualized Therapies. Weinheim: WILEY-VCH, 2002: 215-34
11. Rothstein MA, Epps PG: Ethical and legal implications of pharmacogenomics. Nat Rev Genet, 2001; 2(3): 228-31
12. Cooper RS, Kaufman JS, Ward R: Race and Genomics. N Engl J Med, 2003; 348(12): 1166
13. Burchard EG, Ziv E, Coyle N et al: The Importance of Race and Ethnic Background in Biomedical Research and Clinical Practice. N Engl J Med, 2003; 348(12): 1170
14. Vaszar LT, Cho MK, Raffin TA: Privacy issues in personalized medicine. Pharmacogenomics, 2003; 4(2): 107-12
15. Moldrup C: Ethical, Social and Legal Implications of Pharmacogenomics: A Critical Review. Community Genetics, 2001; 4(4): 204-14
16. Anderlik MR, Rothstein MA: Privacy and Confidentiality of Genetic Information: What Rules for the New Science? Annu Rev Genom Hum Genet, 2001; 2(1): 401-33
17. Evans WE, Relling MV: Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science, 1999; 286(5439): 487
18. Meyer JM, Ginsburg GS: The path to personalized medicine. Curr Opin Chem Biol, 2002; 6(4): 434-38
19. Ginsburg GS, McCarthy JJ: Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol, 2001; 19(12): 491-96
20. Ross JS, Ginsburg GS: The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice. Am J Clin Pathol, 2003; 119(1): 26-36
21. st May, 2002. Expert Rev Mol Diagn, 2002; 2(4): 299-301
22. Gärdenfors P: Conceptual Spaces: The Geometry of Thought. Cambridge MA, London: The MIT Press, 2000
23. Mancinelli L, Cronin M, Sadee W: Pharmacogenomics: the promise of personalized medicine. AAPS Pharm Sci, 2000; 2(1): E4. Available from: URL: http://www.aapspharmsci.org/ps0201/ps020104/ps020104.pdf
24. Liotta LA, Kohn EC, Petricoin EF: Clinical Proteomics: Personalized Molecular Medicine. JAMA, 2001; 286(18): 2211
25. Kalow W: Pharmacogenetics and personalised medicine. Fundam Clin Pharmacol, 2002; 16(5): 337-42
26. Moxon R, Tang C: Challenge of investigating biologically relevant functions of virulence factors in bacterial pathogens. Philos Trans R Soc Lond B Biol Sci, 2000; 355(1397): 643-56
27. Martinez JL, Baquero F: Interactions among Strategies Associated with Bacterial Infection: Pathogenicity, Epidemicity, and Antibiotic Resistance. Clin Microbiol Rev, 2002; 15(4): 647-79
28. Wilson JW, Schurr MJ, LeBlanc CL et al: Mechanisms of bacterial pathogenicity, Postgrad Med J, 2002; 78(918): 216
29. Tyers M, Mann M: From genomics to proteomics. Nature, 2003; 422(6928): 193-97
30. Gerling IC, Solomon SS, Bryer-Ash M: Genomes, Transcriptomes, and Proteomes: Molecular Medicine and Its Impact on Medical Practice. Arch Intern Med, 2003; 163(2): 190
31. Valet GK, Tarnok A: Cytomics in predictive medicine. Cytometry 2003; 53B(1): 1-3. Available from: URL: http://www.biochem.mpg.de /valet/cellclas.html
32. Guttmacher AE, Collins FS: Genomic medicine a primer. N Engl J Med, 2002; 347(19): 1512-1520. Available from: URL: http://content.nejm.org/cgi/reprint/ 347/19/1512.pdf
33. Hanash S: Disease proteomics. Nature 2003; 422(6928): 226-32
34. Weil J: Genetic counselling in the era of genomic medicine: As we move towards personalised medicine, it becomes more important to help patients understand genetic tests and make complex decisions about their health. EMBO Reports 2002; 3(7): 590-93
35. Burgner D, Levin M: Genetic susceptibility to infectious diseases. Pediatr Infect Dis J, 2003; 22(1): 1-6
36. Evans WE, McLeod HL: Pharmacogenomics - Drug Disposition, Drug Targets, and Side Effects. N Engl J Med, 2003; 348(6): 538-49. Available from: URL: http://content.nejm.org/cgi/reprint/348/6/538.pdf
37. Weinshilboum R: Inheritance and Drug Response. N Engl J Med, 2003; 348(6): 529-37. Available from: URL: http://content.nejm.org/cgi /reprint/348/6/529.pdf
38. Tirona RG, Kim RB: Pharmacogenomics of Drug Transporters. In: Licinio J, Wong M-L, editors. Pharmacogenomics: The Search for Individualized Therapies. Weinheim: WILEY-VCH, 2002: 179-213
39. Fromm MF, Eichelbaum M: The Pharmacogenomics of Human P-Glycoprotein. In: Licinio J, Wong M-L, editors. Pharmacogenomics: The Search for Individualized Therapies. Weinheim: WILEY-VCH, 2002: 159-78
40. Schwab M, Eichelbaum M, Fromm MF: Genetic Polymorphisms of the Human MDR1 Drug Transporter. Annu Rev Pharmacol Toxicol, 2003; 43(1): 285-307
41. Telenti A, Aubert V, Spertini F: Individualising HIV treatment - pharmacogenetics and immunogenetics. Lancet, 2002; 359(9308): 722-23
42. Murphy MP: Current pharmacogenomic approaches to clinical drug development. Pharmacogenomics, 2000; 1(2): 115-23
43. Shi MM, Bleavins MR, de la Iglesia FA: Pharmacogenetic Application in Drug Development and Clinical Trials. Drug Metab Dispos, 2001; 29(4): 591. Available from: URL: http://dmd.aspetjournals.org/cgi/reprint/29/4/591.pdf
44. Visser A, Deccache A, Bensing J: Patient education in Europe: united differences. Patient Educ Couns, 2001; 44(1): 1-5
45. Fierz W: Information management driven by diagnostic patient data: right information for the right patient. Expert Rev Mol Diagn, 2002; 2(4): 355-60
46. Hersh WR: Medical informatics: improving health care through information. JAMA, 2002; 288(16): 1955-58
47. nd ed. New York: Springer-Verlag, 2003
48. McEntyre J, Lipman D: PubMed: bridging the information gap. CMAJ, 2001; 164(9): 1317. Available from: URL: http://www.cmaj.ca/cgi/reprint/164/9/1317.pdf
49. Anonymous: High Wire Press Is 5 years old. J Biol Chem, 2000; 275(15): 10717. Available from: URL: http://www.jbc.org/cgi/reprint/275/15/10717.pdf
50. Tatusova TA, Karsch-Mizrachi I, Ostell JA: Complete genomes in WWW Entrez: data representation and analysis. Bioinformatics, 1999; 15(7): 536. Available from: URL: http://bioinformatics.oupjournals.org/cgi/reprint/15/7/536. pdf
51. Thorisson GA, Stein LD: The SNP Consortium website: past, present and future. Nucl Acids Res, 2003; 31(1): 124. Available from: URL: http://nar.oupjournals.org/cgi/reprint/31/1/124.pdf
52. Hewett M, Oliver DE, Rubin DL et al: PharmGKB: the Pharmacogenetics Knowledge Base. Nucl Acids Res, 2002; 30(1): 163-65. Available from: URL: http://nar.oupjournals.org/cgi/reprint /30/1/163.pdf
53. Consortium TGO: Creating the Gene Ontology Resource: Design and Implementation. Genome Res, 2001; 11(8): 1425. Available from: URL: http://www.genome.org/cgi/reprint/11/8/1425.pdf
54. Zinkernagel RM: On natural and artificial vaccinations. Annu Rev Immunol, 2003; 21: 515-46
55. Alcami A: Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol, 2003; 3(1): 36-50
56. Chaston TB, Lidbury BA: Genetic 'budget' of viruses and the cost to the infected host: a theory on the relationship between the genetic capacity of viruses, immune evasion, persistence and disease. Immunol Cell Biol, 2001; 79(1): 62-66
57. Haig DM: Subversion and piracy: DNA viruses and immune evasion. Research in Veterinary Science, 2001; 70(3): 205-19
58. Cummings CA, Relman DA: Using DNA microarrays to study host-microbe interactions. Emerg Infect Dis 2000; 6(5): 513-525. Available from: URL: http://www.cdc.gov/ncidod/eid/vol6no5/pdf/cummings.pdf
59. Kotb M, Norrby-Teglund A, McGeer A et al: An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med, 2002; 8(12): 1398-404
60. Loong CV: Bacterial Genomes and Infectious Diseases. Pediatr Res, 2003; 01
61. Huang SH, Triche T, Jong AY: Infectomics: genomics and proteomics of microbial infections. Funct Integr Genomics, 2002; 1(6): 331-44
62. Aujame L, Burdin N, Vicari M: How Microarrays Can Improve Our Understanding of Immune Responses and Vaccine Development. Ann NY Acad Sci, 2002; 975(1): 1-23
63. Geraghty DE: Genetic diversity and genomics of the immune response. Immunol Rev, 2002; 190: 5-8
64. Hill AVS. Immunogenetics and genomics. The Lancet 2001; 357(9273): 2037-41. Available from: URL: http://pdf.thelancet.com/pdfdownload?uid=llan.357. 9273.editorial_and_re view.16672.1&x=x.pdf
65. Fierz W: Basic problems of serological laboratory diagnosis. Mol Biotechnol, 1999; 13(2): 89-111
66. Robertson JA, Brody B, Buchanan A et al: Pharmacogenetic challenges for the health care system. Health Aff (Millwood), 2002; 21(4): 155-67
67. Austin MJF, Kreiner T: Integrating genomics technologies in health care: practice and policy challenges and opportunities. Physiol Genomics, 2002; 8(1): 33-40. Available from: URL: http://physiolgenomics.physiology.org/cgi/reprint/8/ 1/33.pdf
68. st Century. Washington, D.C: National Academic Press, 2001
69. Poste G: Molecular diagnostics: a powerful new component of the healthcare value chain. Expert Rev Mol Diagn, 2001; 1(1): 1-5
70. Picard FJ, Bergeron MG: Rapid molecular theranostics in infectious diseases. Drug Discovery Today, 2002; 7(21): 1092-101
71. Gouget B, Barclay J, Rakotoambinina B: Impact of emerging technologies and regulations on the role of POCT. Clin Chim Acta, 2001; 307(1-2): 235-40
72. Friedman BA: The Total Laboratory Solution: A New Laboratory E-Business Model Based on a Vertical Laboratory Meta-Network. Clin Chem 2001; 47(8): 1526-35. Available from: URL: http://www.clinchem.org/cgi/reprint/47/8/1526.pdf
73. st century. Int J Med Inf 2001; 64(2-3): 111-27
74. Haux R, Ammenwerth E, Herzog W, Knaup P: Health care in the information society. A prognosis for the year 2013. Int J Med Inf, 2002; 66(1-3): 3-21
75. Berg M: Patients and professionals in the information society: what might keep us awake in 2013. Int J Med Inf, 2002; 66(1-3): 31-37
76. Humphreys BL: Electronic Health Record Meets Digital Library: A New Environment for Achieving an Old Goal. J Am Med Inform Assoc, 2000; 7(5): 444-52
77. Collins FS: Medical and Societal Consequences of the Human Genome Project. N Engl J Med, 1999; 341(1): 28
78. Clayton EW: Through the Lens of the Sequence. Genome Res, 2001; 11(5): 659
79. Collins FS, Green ED, Guttmacher AE, Guyer MS: A vision for the future of genomics research. Nature, 2003; 422(6934): 835-47
80. Robertson JA: Consent and privacy in pharmacogenetic testing. Nat Genet, 2001; 28(3): 207-09
81. Swiss Federal Office of Public Health: HIV - aktuelles Wissen zu Test und Diagnostik, 2000. Available from: URL: http://www.suchlundaids.bag.admin.ch/ imperia/md/content/aids/6.pdf
82. Swiss Academy of Medical Sciences: Medical-ethical Guidelines for genetic investigations in humans, 1993. Available from: URL: http://www.samw.ch/ content/Richtlinien/e_Gen.pdf
83. Bundesversammlung der Schweizerischen Eidgenossenschaft: Bundesgesetz über genetische Untersuchungen beim Menschen, 2002. Available from: URL: http://www.admin.ch/ch/d/ff/2002/7481.pdf
84. Breithaupt H: The future of medicine: Centralised health and genetic databases promise to increase quality of health care while lowering costs. But to get there, many legal and social obstacles will have to be overcome to prevent abuse. EMBO Reports, 2001; 2(6): 465
85. Aarts JECM, Berg M, Huisman E: Health Information Management Education at the Institute of Health Policy and Management of the Erasmus Unversity Medical Center. In: Haux R, Kulikowski C, editors. Yearbook of Medical Informatics, 2003. Stuttgart: Schattauer Verlagsgesellschaft GmbH, 2003: 179-83
86. Greenbaum D, Luscombe NM, Jansen R et al: Interrelating Different Types of Genomic Data, from Proteome to Secretome: 'Oming in on Function. Genome Res, 2001; 11(9): 1463. Available from: URL: http://www.genome.org/cgi/reprint/11/9/ 1463.pdf
87. Orphanides G: Toxicogenomics: challenges and opportunities. Toxicology Letters, 2003; 140-141: 145-48
88. Funkhouser J: Reinventing pharma: The theranostic revolution. Curr Drug Discovery, 2002; 8: 17-19. Available from: URL: http://www.currentdrugdiscovery. com/pdf/2002/8/Funkhouser%20.pdf
89. Bogdanovic S, Langlands B: Theranostics: Commercial Opportunities for Diagnostic and Pharmaceutical Companies. Westborough: D&MD Publications Inc, 2001